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Epoprostenol (PGI2, Prostacyclin) During
High-Risk Hemodialysis: Preventing
Further Bleeding Complications
Richard D. Swartz, MD, Walter Flamenbaum, MD, Alan Dubrow, MD,
Jane C. Hall, MS, James W. Crow, PhD, Alan Cato, MD
The frequency of hemodialysis-associated hemorrhage was studied prospectively in two
successive, parallel, heparin-controlled studies using epoprostenol (PGI2; average dose,
4.1 ng/kg- mm) as the sole antithrombotic agent. Sixty-three patients with active or
recently active bleeding underwent 163 hemodialysis treatments in each of which pro-
spective bleeding risk was assessed. PGI2 was associated with up to 50% overall reduc-
tion in the frequency of bleeding, particularly in the highest risk circumstances. PGI2
also allowed successful completion of the full, pros pectively prescribed hemodialysis
time in the most treatments (82% versus 93% with heparin). Furthermore, the efficiency
of hemodialysis using PGI2, as indicated by the reduction in concentration of blood urea
nitrogen and serum creatinine, was equal to that using heparmn, even though there was a
tendency toward modest reduction in residual volume of the hollow fiber dialyzer and
slightly more frequent early termination of treatment from dialyzer clotting with PGI2.
No severe vasodilatory side effects of PGI2 were observed during these studies. Hypoten-
sion was equally frequent durir.g hemodialysis with heparin as with PGI2. The current
results suggest that PGI2 should be considered as a substitute for heparin during high-risk
hemodialysis because PGI2 may reduce the incidence of dialysis-associated bleeding
without severe adverse side effects.
H emodialysis may improve the qualitative plate-
let abnormality of uremia and reduce the
bleeding tendency in patients with acute or chronic
renal failure. However, the requirement for heparin
to prevent extracorporeal clotting during hemodial-
ysis may actually increase the risk of new or wors-
ened bleeding among patients already at higher risk.
As a result, there is considerable interest in develop-
ing methods, such as controlled dosing of heparin, 1-5
to minimize the danger to the bleeding patient.
When analyzed rigorously and systematically,8 re-
gional heparinization with protamine6’7 has proven
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cumbersome to perform and ineffective compared
with low-dose heparin in preventing bleeding com-
plications. Regional anticoagulation with citrate9 is
also cumbersome and is not yet widely used or ac-
cepted. Hemodialysis without anticoagulation1012
and hemodialysis with intermittent saline washout
only13 have also been advocated.
Epoprostenol (prostacyclin, PGI2) is a short-acting
inhibitor of platelet aggregation at doses below those
causing marked vasodilatation.1417 In vitro and in
vivo studies show that platelet loss during extracor-
poreal circulation can be reduced using PGI2.1822
Cardiopulmonary bypass192#{176} and hemodialysis,2’23
among extracorporeal circulatory procedures, have
been both feasible and effective with PGI2 and re-
duce extracorporeal platelet loss with few serious
adverse effects. As a short-acting agent, PGI2 may
prove useful during hemodialysis not only in pre-
venting clotting of the extracorporeal circuit but also
in reducing bleeding in patients at risk.2427
The current parallel, heparin-controlled study
compares the results of hemodialysis with PGI2 to
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those with tightly monitored, low-dose heparin for
patients with increased bleeding risk.
METHODS
The experience described here includes two con-
trolled studies, the first (study A), a rigorous pilot
performed at two major centers between December
1982 and November 1983 and the second (study B),
a wider study performed at six centers between De-
cember 1983 and March 1984. The only differences
between the two studies were the more intense eval-
uation for drug effect and side effects in study A, and
the maximum duration of six hemodialysis treat-
ments in the initial study (study A) versus three
treatments in study B.
Subjects
All patients were between the ages of 18 and 80
years, needed hemodialysis for complications of
acute or chronic renal failure, and were at increased
risk for bleeding at the time of hemodialysis. Sub-
jects were identified 24 hours or more before entry
into the study. Informed consent was obtained con-
sistent with the guidelines of the institutional re-
view boards of the participating institutions. Exclu-
sion criteria included only pregnancy and severe
cardiovascular instability.
Bleeding Risk
The recognition of bleeding risk was based on the
clinical judgment of participating physicians at each
center. The site of bleeding risk was specifically
identified before entry into the study, although
change in site of risk was assessed for each subse-
quent hemodialysis as well.
The degree of bleeding risk was categorized on the
basis of the hemorrhagic risk just before initiation of
each hemodialysis. Four risk categories were identi-
fied within 24 hours before each treatment as pre-
viously described8: very high, actively bleeding at
the time of hemodialysis; high, active bleeding or
new surgical wound within 3 days of hemodialysis;
moderate, active bleeding or new surgical wound
within 3 to 7 days of hemodialysis; and low, no active
bleeding or wound within 7 days of hemodialysis.
Patient Assignment
Patients entered the study chronologically and con-
secutively. Within each participating center patients
were randomized either to heparin or to PGI2 within
each initial risk category on the day of screening
(usually within 24 hours of the first study hemodial-
ysis).
All subjects then underwent a course of hemodial-
ysis using the assigned agent (up to six hemodialyses
in the first study and up to three hemodialyses in the
second study). Again, degree and site of risk were
reassessed for the purposes of analysis before each
hemodialysis, although the initial random assign-
ment was not changed. A course of hemodialysis for
a given patient was terminated at the discretion of
participating physicians, based on the occurrence of
(1) clinical complications related or unrelated to the
study agent, (2) mechanical complications with he-
modialysis itself, or (3) no further need for acute
hemodialysis during the study course.
Hemodialysis Specifications
All hemodialyses were carried out using high so-
dium, bicarbonate, single-pass dialysate systems.
Hollow fiber dialyzers of the cellulose acetate or cu-
prophane type were used in almost all instances.
Occasional dialysis was performed using parallel
plate devices at the discretion of the investigators.
Vascular access was that chosen by, and available to,
the physicians, and included two-needle fistula or
graft access, single-needle central venous access and
double-lumen central venous access.
Drug Protocols
For patients assigned to heparin, a low-dose protocol
was based on loading doses below 20 U/kg and
maintenance infusion rates below 20 U / kg. hr. Pa-
tients were monitored and infusion rates were ad-
justed to maintain the activated clotting time or the
thrombin clotting time at a maximum of 1.5 to 2
times the baseline value.
PGI2 in glycine buffer (synthesized by The Up-
john Company, Kalamazoo, MI, and formulated by
Wellcome Foundation Limited, Research Triangle
Park, NC) was administered as an infusion at 4
ng/kg/min given for 10 minutes before hemodialy-
sis intravenously through the venous dialysis access
and throughout hemodialysis into the hemodialysis
circuit between the blood pump and the dialyzer.
Infusion rates were adjusted downward for side ef-
fects or upward toward 8 ng/kg/min for evidence
of early clotting in the extracorporeal circuit. Doses
were based on previously described platelet inhibi-
tion studies.1827
Study Assessments
Hemodialysis efficiency was assessed on the basis of
completion of prescribed treatment without me-
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Patients 9 13 22 19 31 32
Hemodialyses 28 31 54 48 82 79
Mean age 49 47 53 51 52 50
M:F 8:1 4:9 9:13 9:10 17:14 13:19
Renal failure (patients)
Acute 4 4 5 5 9 9
Chronic 5 9 17 14 22 23
Bleeding site (patients)
Surgical trauma 5 7 11 11 16 18
UGI/LGI 4 3 11 7 15 10
GU/Gyn 1 1 1 1 2 2
Respiratory 0 2 0 1 0 3
Bleeding risk (dialyses)
Very high 11 8 18 19 29 27
High 8 9 25 22 33 31
Moderate 6 10 10 7 16 17
Low 3 4 1 0 4 4
Hep: heparin; Epo: epoprostenol. Bleeding risk is that at the time of each dialysis.
Some patients had more than one bleeding site.
chanical or clinical complication and solute removal
indicated by comparison of concentrations of blood
urea nitrogen and serum creatinine before hemodi-
alysis with those after hemodialysis. Direct mea-
surement of clearance and ultrafiltration were un-
dertaken but were cumbersome and difficult to stan-
dardize because neither blood flow rates nor
dialyzer type and size were controlled. Therefore,
clearance and ultrafiltration data are not reported
here.
Dialyzer clotting was assessed on the basis of re-
sidual dialyzer volume after treatment as measured
by air washout technique and the frequency of early
termination of treatment because of clotting compli-
cations.
Hemorrhage was determined during the first 24
hours after initiation of hemodialysis by direct evi-
dence for active bleeding at the visible primary site
of risk, as well as indirect evidence for bleeding on
the basis of change in serial hematocrit determina-
tions. Definite bleeding was considered to have oc-
curred when there was reduction in hematocrit of 3
vol % or more not explained by positive fluid bal-
ance or by infusion of hyperoncotic or hyperosmotic
agents (albumin, plasma, mannitol, etc.) or when
failure of hematocrit to increase in the face of trans-
fusion was unexplained by similar factors. Hemo-
lysis was considered on clinical grounds in these
assessments but was seldom identified as an impor-
tant consideration.
Signs and symptoms during hemodialysis were
recorded, graded in severity, and assessed according
to direct or indirect relation to the pharmacologic
agent, heparin, or PGI2 used during treatment.
Statistical Methods
The Student’s t test was used to compare observed
mean values between groups, and the chi-square
test to compare the frequency of observed results
between groups.
RESULTS
During the course of the two controlled studies de-
scribed here, 63 patients underwent a total of 161
hemodialyses. Table I describes the clinical charac-
teristics of the patients studied, showing the compa-
rability of patients dialyzed using each study agent.
Bleeding sites are listed as those on the day of the
first hemodialysis. The frequency of bleeding risk is
listed as the number of total hemodialyses in which
bleeding occurred for each risk category.
Hemodialysis efficiency was determined by com-
parison of blood urea nitrogen and serum creatinine
concentration values taken before hemodialysis to
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TABLE II
Dialysis Efficiency as Indicated by Reduction In Solute Concentration During Dialysis
Study A Study B Totals
Hep Epo Hop Epo Hop Epo
No. (hemodialyses) 23 30 52 44 75 74
Blood urea nitrogen
Mean 1.58 1.71 2.30 2.06 2.15 1.92
SD .26 .33 .69 .62 .75 .55
Creatinine
Mean 1.48 1.61 1.95 1.84 1.81 1.75
SD .52 .42 .48 .44 .53 .45
Ratio of values measured before hemodialysis (pre) to that after hemodialysis and Epo were not significant in any pair shown in this table. Hep = heparin; Epo
(post), irrespective of dialyzer type or blood flow rate. Differences between Hep = epoprostenol.
those taken after hemodialysis, where available, more frequent with PGI2 than with heparin. Finally,
Table II shows that the ratio of pretreatment values premature termination of hemodialysis because of
to posttreatment values were not different compar- clotting in the extracorporeal system (needles, lines,
ing heparin with PGI2 for either study or for all he- traps, dialyzer) was also statistically more frequent
modialyses. with PGI2 during study B and overall. Such clotting
Dialyzer clotting as indicated by residual dialyzer complications resulted in dropout from the study by
volume was determined successfully in most of the three patients treated with PGI2 but did not even-
hemodialyses, and results are shown in Table III. tuate in other serious complications.
Values of mean posttreatment dialyzer volume Frequency of bleeding complications was assessed
tended to be somewhat lower with PGI2 than with in the 24 hours after initiation of hemodialysis on
heparin, although this difference was not statisti- the basis of detectable blood loss both for each mdi-
cally significant and was not reflected in signifi- vidual hemodialysis, as well as for the total course of
cantly reduced solute clearance. Reduction in dia- each patient. Table IV shows that the incidence of
lyzer volume by 20% (post/pre ratio below .80) and bleeding complications per dialysis with heparin
50% (post/pre ratio below .50), respectively, were was greater than that with PGI2 overall. Bleeding
TABLE Ill
Indicators of Dlalyzer Clotting
Study A Study B Totals
Hop Epa Hep Epo Hop Epo
No. (hemodialyses) 24 29 41 37 65 66
Residual dialyzer volume
Mean .69 .56 .68 .52 .65 .54
SD .24 .23 .22 .29 .22 .21
Residual dialyzer volume
Below .80 63% 79% 68% 84% 66%* 82%
Below .50 33% 38% 20%* 41% 25%t 39%
Premature termination
or hemodialysis 11% 13% 4%1 23% 6% 19%
* P < .05. (chi-square test). Below .80 and below .50 denote postdialysis volume less than 80% and 50%.
f P < .10. (chi-square test). respectively, of predialysis volume. Values are expressed as percent of available
P < .02. (chi-square test). observations.
Residual dialyzer volume expressed as ratio of postdialysis volume to predi- Premature termination of dialysis due to clotting complication.
alysis volume. Hep = heparin; Epo = epoprostenol.
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TABLE IV
Frequency of BleedIng Complications Among Risk Groups
Study A Study B Totals
Hep Epa Hop Epo






Total 50* 16 37 29 41b 24
Very high risk ioo#{176} 63 78d 53
High risk 13 0 24 18
Very high and high risk 63i 29 47 34









First hemodialysis 56 25 65b 26






Total 67d 31 64 47





* Frequency of bleeding expressed as percent incidence among total hemo- #{149}P < .01 (chi-square test).
dialyses observed. b P < .02 (chi.square test).
t Frequency of bleeding expressed as percent incidence among total patients P < .05 (chi-square test).
studied. d p < .10 (chi-square test).
Hep = heparin; Epo = epoprostenol.
was also more frequent among the higher risk
groups, particularly the groups with bleeding that
was active (VH, very high risk) or recent (H, high
risk), and among all first-dialysis treatments or all
first and second hemodialysis treatments combined.
Furthermore, the total number of patient courses
complicated by hemodialysis-associated bleeding, as
well as the number of patient courses in which
bleeding risk persisted, as marked by either (1) fail-
ure of bleeding risk to improve over time because of
continued or renewed bleeding or (2) study termina-
tion because of bleeding complication, also tended to
be higher with heparin. Dropout from the study be-
cause of severe bleeding requiring some interrup-
tion of the course of hemodialysis and/or acute in-
tervention, such as surgery, occurred during seven
courses of hemodialysis with heparin and during
only one course with PGI2.
Severity of bleeding was also evaluated during the
24 hours after initiation of hemodialysis, on the basis
of quantitative assessment of hematocrit reduction
relative to transfusion and parenteral fluid require-
ment. Among the 34 patients treated with heparin in
whom bleeding complications occurred, this bleed-
ing was judged to be mild (hematocrit change 3 vol
% or less without transfusion) in 6 of 34 instances,
moderate (requiring transfusion but with hemato-
crit change 5 vol % or less) in 17 of 34 instances, and
severe (hematocrit change above 5 vol % with or
without transfusion) in 11 of 34 instances. Among
the 19 patients treated with PGI2 in whom bleeding
complications occurred, this bleeding was judged to
be mild in 8 of 19, moderate in 5 of 19, and severe in
6 of 19 instances. Although there was a tendency
toward fewer severe episodes with PGI2, these dis-
tributions of severity were not statistically different.
Total doses of heparin averaged 55.8 U / kg during
hemodialysis in both studies, ranging from 13.5
U/kg to 104.4 U/kg, and heparin doses did not
differ between risk groups. Furthermore, heparin
doses did not differ in hemodialyses complicated by
bleeding. Total PGI2 doses averaged 4.1 ng/kg. mm
during hemodialysis in both studies, ranging from
0.5 to 8.6 ng/kg#{149}min. PGI2 doses did not differ sta-
tistically between risk groups, and PGI2 doses also
did not differ in hemodialyses associated with
bleeding. Finally, neither heparin, PGI2 doses, nor
predialysis hematocrit level correlated with clotting
complications as indicated by reduction in post-
treatment dialyzer volume.
The incidence of adverse drug effects among the
study dialyses is summarized in Table V. Although
the incidence of nausea and vomiting, flushing, or
headache was somewhat higher with PGI2, these
side effects were uniformly mild or moderate in de-
gree, responded to reduction in PGI2 dose and/or
conservative intervention such as saline or position
change, and did not result in termination of hemodi-
alysis in any instances. Overall, the incidence of
mild or severe hypotension was not higher with
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TABLE V
Adverse Reactions DurIng Hemodialysis
Study A Study B Totals
Adverse Reaction Hop Epo Hep Epa Hop Epa
No. patients 28 33
Hypotension 15 (1) 13 (1)
Chest pain 1 0
Abdominal pain, nausea 1(1) 5
Headach 0 6
Flushing 0 2
55 48 83 81
24 (1) 20 (2) 39 (2) 33 (3)
1(1) 2 2 (1) 2
1 2 2 (1) 7
0 5 0 11
0 4 0 6
Hep = heparin; Epo = epoprostenol. Number of adverse reactions expressed
as total number of reactions (number of serious reactions). Other adverse reac-
tions such as arrhythmia, seizure, or myocardial ischemia were not observed
during this study. There were no significant differences between Hep and Epo for
any of pair of values shown.
PGI2. One epidose of severe hypotension with PGI2
resulted from malfunction of the drug infusion
pump and inadvertent infusion of a large drug dose;
however, discontinuation of infusion reversed the
episode successfully and the patient was withdrawn
from the study.
DISCUSSION
Hemorrhage remains a serious complication not
only of uremia but also of the hemodialysis proce-
dure. Numerous reports document the incidence of
unexpected bleeding at various sites in hemodialysis
patients, including the central nervous system,28 ret-
roperitoneum,29 mediastinum and pericardium, 30.31
eye,32 kidney,33 and liver.34 These unexpected
bleeding complications are observed in addition to
more predictable bleeding from common sites,such
as the gastrointestinal tract and surgical or traumatic
wounds.3539 Furthermore, platelet losses during he-
modialysis may aggravate the already high bleeding
risk.40
To prevent further hemorrhage in the hemodialy-
sis patient already bleeding or at high risk, the de-
gree of systemic anticoagulation must be limited
during the extracorporeal circulation. Hemodialysis
with low-dose heparinization and hemodialysis
without anticoagulation are the most widely ac-
cepted methods, although it is documented by rigor-
ous follow-up that bleeding may continue with low-
dose heparinization.5 Regionalized extracorporeal
anticoagulation procedures have proven cumber-
some to perform and monitor, with heparin/prot-
amine proving no more effective than low-dose hep-
arm in preventing hemorrhage8’41 and with citrate/
calcium not widely tested or accepted. Heparin
impregnation of hemodialysis surfaces,4244 other
nonthrombogenic materials,45’46 and heparinase de-
vices in the extracorporeal circuit47 have been de-
scribed but unavailable for clinical use. Finally,
peritoneal dialysis completely obviates the use of
anticoagulant agents when this method can be used
in the patient with increased bleeding risk.
The results of the current study suggest that PGI2,
a short-acting agent that inhibits platelet aggrega-
tion, can routinely prevent extracorporeal clotting
and allow hemodialysis equally efficient to that with
low-dose heparin. More important, when compared
with low-dose heparin in patients at increased risk,
hemodialysis with PGI2 may reduce the frequency
of associated hemorrhage and promote resolution of
the course of bleeding during successive hemodialy-
sis treatments. Finally, although there is a tendency
to increased dialyzer clotting with PGI2, the average
reduction of blood urea nitrogen and serum creati-
nine concentrations and the incidence of adverse
effects compare favorably with hemodialysis with
heparin.
The assessment of bleeding complications during
and immediately after hemodialysis is difficult. In
many instances the subjective assessment by the cli-
nician does not correspond to blood loss quantifiable
by changes in hematologic parameters. Careful and
intensive follow-up, not only for visible evidence of
bleeding but also for reduction in RBC indicators
that signal bleeding complications, is essential for
any study evaluating hemorrhage in acutely ill pa-
tients. Unfortunately, few studies of bleeding in the
hemodialysis patient present such information,
making comparison with the current study difficult.
The incidence of bleeding reported in a controlled
trial of regional heparinization,8 with low-dose hep-
arm,5 and in studies of acute hemodialysis6’39 are
comparable in magnitude to that reported here, and
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confirm the trend toward the improvement ob-
served with PGI2 use.
The objective assessment of severity when bleed-
ing occurs is even more difficult than assessment of
bleeding frequency. Subjectivity confounds even
the quantitation of hematocrit change, because de-
cisions to administer blood or other volume ex-
panders are clinical judgments based on many fac-
tors in addition to bleeding. However, even though
analysis of bleeding severity is less objective than
analysis of bleeding frequency, the data reported
here suggest that moderate and severe bleeding may
be reduced in frequency with PGI2.
There has been some concern that the antiaggre-
gating effect of PGI2 may be sufficiently prolonged to
negate the advantage of PGI2 for hemodialysis.48
However, several studies have shown that dose-re-
lated platelet inhibition often lasts fewer than 5 or 10
minutes at doses below 5 ng/kg. mm, and that
beyond 30 minutes residual platelet inhibition is less
than 20%.’#{176} Furthermore, the current results with
respect to bleeding complications suggest that PGI2
may be advantageous compared with low-dose hep-
arm and that concern regarding prolonged platelet
inhibition may be unwarranted. Development of
similar agents with shorter duration of action may
prove even more effective in accomplishing the dual
goals in hemodialysis.
Severe adverse effects would be a serious draw-
back to the widespread use of an agent such as PGI2.
The current experience suggests, however, that al-
though some side effects were more frequent with
PGI2, these side effects were seldom severe and did
not prevent the use of the agent during hemodialy-
sis. Hypotension was not a particular problem with
PGI2 in these studies, although we used only bicar-
bonate, high-osmolality dialysate as suggested in
previous studies.23 Fortunately, the aggregation
inhibition by PGI2 usually occurs at doses lower
than those generally employed in this study and
lower than those that generally cause vasodila-
tion.1416’23’49’5#{176}Therefore, if hypotension occurs dur-
ing hemodialysis with PGI2, doses may be reduced
and still retain the antiaggregating effect.
The major adverse event with PGI2 in the current
study appeared to be a tendency for increased extra-
corporeal clotting marked by modest reduction in
functional dialyzer volume and by occasional early
termination of hemodialysis. Other methods of lim-
iting the bleeding risk, particularly hemodialysis
without anticoagulation, have not been -systemati-
cally compared to standard low-dose heparin or to
PGI2 with respect to extracorporeal clotting and
early termination of hemodialysis. In fact, recent
uncontrolled hemodialysis experience without anti-
coagulant suggests that dialyzer clotting occurs in
more than 10% of treatments, often requires chang-
ing of the dialyzer and lines during treatment, and
results in average extracorporeal blood loss exceed-
ing 150 mL.12
In conclusion, hemorrhage remains an important
and frequent complication of hemodialysis, often
exacerbated by the required use of anticoagulants
during the procedure. The current study describes
the successful use of PGI2, a short-acting antiaggre-
gating agent, in a controlled comparison with stan-
dard low-dose heparmnization for hemodialysis of pa-
tients with increased risk for bleeding. PGI2 was as-
sociated with a lower incidence of bleeding
complications in the highest risk patients, no serious
adverse effects,and only a modest increase in extra-
corporeal clotting. Based on results of this type,
agents such as PGI2 should be considered in patients
with serious bleeding risk who require hemodialy-
sis. Furthermore, controlled studies of other
methods, new agents, or new devices are warranted
in an effort to improve the safety and effectiveness of
hemodialysis in the acute, high-risk setting.
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